Objective To describe patient perspectives on recruitment and retention in clinical trials.
Study Design and Setting Systematic review of qualitative studies that reported the …

Racial inequities are well-documented across the gynecologic oncology care continuum,
including the representation of racial and ethnic minoritized groups (REMGs) in gynecologic …

Background According to the Food and Drug Administration, African Americans (AAs) have
been habitually underrepresented in cancer clinical trials (CCTs). This under-enrolment has …

We define cancer equity as all people having as the same opportunity for cancer prevention,
treatment, and survivorship care. However, marginalized populations continue to experience …

Cancer disproportionately impacts racial/ethnic minority groups, yet they remain
underrepresented in cancer clinical trials. This commentary highlights strategies for …

Although there has been an increase focus on recruitment of minority populations at safety-
net hospitals into cancer clinical trials, there is still a paucity of research exploring minority …

The COVID-19 pandemic that continues to ravage communities all over the United States is
serving to highlight some of the long-standing inequities that have plagued our nation. At the …

Background Although the importance of care coordination (CC) is well-recognized, cancer
patients often receive poorly coordinated care across varied care settings and different …

Background Participating in clinical trials is a metric of high-quality cancer care and
improves survival. However, Black individuals with cancer are less likely to be enrolled in …

Background Racial and ethnic inequities exist in cancer clinical trial participation. Low
recruitment across ethnically diverse communities contributes to health inequalities further …